279 related articles for article (PubMed ID: 25237892)
1. The evaluation of recombinant LH supplementation in patients with suboptimal response to recombinant FSH undergoing IVF treatment with GnRH agonist down-regulation.
Yazıcı Yılmaz F; Görkemli H; Çolakoğlu MC; Aktan M; Gezginç K
Gynecol Endocrinol; 2015 Feb; 31(2):141-4. PubMed ID: 25237892
[TBL] [Abstract][Full Text] [Related]
2. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
Vuong TN; Phung HT; Ho MT
Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
[TBL] [Abstract][Full Text] [Related]
3. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
[TBL] [Abstract][Full Text] [Related]
4. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study.
König TE; van der Houwen LE; Overbeek A; Hendriks ML; Beutler-Beemsterboer SN; Kuchenbecker WK; Renckens CN; Bernardus RE; Schats R; Homburg R; Hompes PG; Lambalk CB
Hum Reprod; 2013 Oct; 28(10):2804-12. PubMed ID: 23838159
[TBL] [Abstract][Full Text] [Related]
5. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
Hohmann FP; Macklon NS; Fauser BC
J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
[TBL] [Abstract][Full Text] [Related]
6. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R
Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
[TBL] [Abstract][Full Text] [Related]
7. A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or poor ovarian reserve: a retrospective analysis.
Dahan MH; Agdi M; Shehata F; Son W; Tan SL
Eur J Obstet Gynecol Reprod Biol; 2014 Jan; 172():70-3. PubMed ID: 24314801
[TBL] [Abstract][Full Text] [Related]
8. Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures.
Ruvolo G; Bosco L; Pane A; Morici G; Cittadini E; Roccheri MC
Fertil Steril; 2007 Mar; 87(3):542-6. PubMed ID: 17126339
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial.
De Placido G; Alviggi C; Perino A; Strina I; Lisi F; Fasolino A; De Palo R; Ranieri A; Colacurci N; Mollo A;
Hum Reprod; 2005 Feb; 20(2):390-6. PubMed ID: 15576390
[TBL] [Abstract][Full Text] [Related]
10. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
11. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulation hormone during induced ovarian stimulation in the GnRH-agonist protocol: a meta-analysis.
Oliveira JB; Mauri AL; Petersen CG; Martins AM; Cornicelli J; Cavanha M; Pontes A; Baruffi RL; Franco JG
J Assist Reprod Genet; 2007; 24(2-3):67-75. PubMed ID: 17195098
[TBL] [Abstract][Full Text] [Related]
12. Comparison of stimulation with clomiphene citrate in combination with recombinant follicle-stimulating hormone and recombinant luteinizing hormone to stimulation with a gonadotropin-releasing hormone agonist protocol: a prospective, randomized study.
Weigert M; Krischker U; Pöhl M; Poschalko G; Kindermann C; Feichtinger W
Fertil Steril; 2002 Jul; 78(1):34-9. PubMed ID: 12095487
[TBL] [Abstract][Full Text] [Related]
13. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
[TBL] [Abstract][Full Text] [Related]
14. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment?
Ren J; Sha A; Han D; Li P; Geng J; Ma C
Fertil Steril; 2014 Jul; 102(1):75-81. PubMed ID: 24746740
[TBL] [Abstract][Full Text] [Related]
15. IVF/ICSI outcome and serum LH concentration on day 1 of ovarian stimulation with recombinant FSH under pituitary suppression.
Bjercke S; Fedorcsak P; Abyholm T; Storeng R; Ertzeid G; Oldereid N; Omland A; Tanbo T
Hum Reprod; 2005 Sep; 20(9):2441-7. PubMed ID: 15919773
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for a suboptimal response to gonadotropin-releasing hormone agonist trigger during in vitro fertilization cycles.
Meyer L; Murphy LA; Gumer A; Reichman DE; Rosenwaks Z; Cholst IN
Fertil Steril; 2015 Sep; 104(3):637-42. PubMed ID: 26149355
[TBL] [Abstract][Full Text] [Related]
17. Outcome of in vitro fertilization in patients with proven poor ovarian responsiveness after early vs. mid-follicular LH exposure: a prospective, randomized, controlled study.
Revelli A; Chiado' A; Guidetti D; Bongioanni F; Rovei V; Gennarelli G
J Assist Reprod Genet; 2012 Sep; 29(9):869-75. PubMed ID: 22644636
[TBL] [Abstract][Full Text] [Related]
18. The effect of LH supplementation to the GnRH antagonist protocol in advanced reproductive ageing women: a prospective randomized controlled study.
Younis JS; Izhaki I; Ben-Ami M
Clin Endocrinol (Oxf); 2016 Jan; 84(1):99-106. PubMed ID: 26304041
[TBL] [Abstract][Full Text] [Related]
19. The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis.
Hill MJ; Levens ED; Levy G; Ryan ME; Csokmay JM; DeCherney AH; Whitcomb BW
Fertil Steril; 2012 May; 97(5):1108-14.e1. PubMed ID: 22365075
[TBL] [Abstract][Full Text] [Related]
20. A relative reduction in mid-follicular LH concentrations during GnRH agonist IVF/ICSI cycles leads to lower live birth rates.
Lahoud R; Al-Jefout M; Tyler J; Ryan J; Driscoll G
Hum Reprod; 2006 Oct; 21(10):2645-9. PubMed ID: 16785261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
